NephrologyOnline.net

Nephrology Xagena

XagenaNewsletter
Xagena Mappa
Medical Meeting
Dermabase.it

Search results for "Renal cell carcinoma"

Post-operative kidney cancer patients show no increased recurrence-free survival ( RFS ) when given the new vitespen vaccine. However a possible improvement in RFS in patients with early stage disea ...


Freezing kidney tumors should be the gold standard or first treatment option for all individuals with tumors that are 4 centimeters in size or smaller. And, this treatment, interventional cryoablati ...


Metanephric neoplasms of the kidney are uncommon, and some cases are associated with papillary carcinoma. Most cases of metanephric adenoma occur in adults, with fewer than 25 cases reported in childr ...


Metanephric adenoma of the kidney is a rare, indolent tumor that may be difficult to differentiate from other small renal masses ( SRMs ). Genetic alterations associated with metanephric adenoma remai ...


Nivolumab ( Opdivo ), an anti-PD-1 immune checkpoint inhibitor, significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, accor ...


Lenvatinib mesylate ( Lenvima ) is an orally administered multiple receptor tyrosine kinase ( RTK ) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endo ...


Aim of a study was to investigate for the presence of existing prognostic factors in patients with bone metastases ( BMs ) from renal cell carcinoma ( RCC ) since bone represents an unfavorable site o ...


Patients with metastatic renal cell carcinoma ( mRCC ) received Sunitinib ( Sutent ) in a global expanded-access program ( EAP ). Researchers have reported the efficacy and safety results for the ...


The aim of a study was to compare survival of resected and unresected patients in a large cohort of patients with metastases to the pancreas from renal cell carcinoma ( PM-RCC ). Data from 16 Itali ...


Top-line results from the CABOSUN randomized phase 2 trial of Cabozantinib ( Cabometyx; Cometriq ) in patients with previously untreated advanced renal cell carcinoma ( RCC ) were announced. The tria ...


Clear cell renal cell carcinoma ( ccRCC ) is well known for its hypervascularity due to the Von Hippel-Lindau/hypoxia-inducible factor dysregulation. Recent findings suggested that copper transporte ...


Pancreatic metastases from renal cell carcinoma are uncommon and their prognostic significance is not well defined. An analysis has evaluated the outcome of patients with pancreatic metastases tre ...


A combination of the immune checkpoint blocker, Avelumab ( Bavencio ), plus the tyrosine kinase inhibitor ( TKI ), Axitinib ( Inlyta ), significantly improves progression-free survival ( PFS ) in pre ...


Cabozantinib ( Cabometyx ) is an oral multitargeted tyrosine kinase inhibitor ( TKI ) that potently inhibits MET and AXL, both associated with poor prognosis in renal cell carcinoma ( RCC ), next to v ...


Cabozantinib ( Cabometyx ) has improved progression-free survival ( PFS ), overall survival ( OS ) and objective response rate ( ORR ) compared with Everolimus in patients with advanced renal cell car ...